Olaparib Plus Pembrolizumab Demonstrates Manageable AEs in Advanced Cholangiocarcinoma
The combination of olaparib and pembrolizumab demonstrated acceptable safety and an manageable adverse effect profile in patients with advanced cholangiocarcinoma who had received prior gemcitabine-based therapy, according to findings from a phase 2 trial. The combination of olaparib (Lynparza) and pembrolizumab (Keytruda) demonstrated acceptable safety and an manageable adverse...
www.onclive.com
Comments / 0